US · PRCT
PROCEPT BioRobotics Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- San Jose, CA 94065
- Website
- procept-biorobotics.com
Price · as of 2025-12-31
$24.63
Market cap 1.27B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $41.63 | +69.02% |
| Intrinsic Value(DCF) | $46.70 | +89.61% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $24.93 | $64.87 | $810,403.40 | $0.00 | $0.00 |
| 2022 | $30.72 | $45.40 | $30,435.46 | $0.00 | $0.00 |
| 2023 | $49.28 | $47.95 | $13,605.22 | $0.00 | $0.00 |
| 2024 | $59.33 | $53.73 | $2,434.77 | $0.00 | $0.00 |
| 2025 | $25.90 | $41.63 | $344.12 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates PROCEPT BioRobotics Corporation's (PRCT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $41.63
- Current price
- $24.63
- AI upside
- +69.02%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$46.70
+89.61% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRCT | PROCEPT BioRobotics Corpo… | $24.63 | 1.27B | +69% | +90% | — | — | -15.10 | 3.94 | 4.69 | -15.09 | — | 3.95 | 63.70% | -33.71% | -31.02% | -24.89% | -74.26% | -18.34% | 0.14 | -11.69 | 6.85 | 5.62 | 2.93 | -171.00% | 3722.00% | -4370.00% | -4.04% | -0.74 | -41.71% | 0.00% | 0.00% | 0.44% | -11.64 | -20.71 | 3.92 | 5.16 |
| AORT | Artivion, Inc. | $38.50 | 1.84B | +35% | -56% | -86% | -88% | 178.92 | 3.90 | 3.96 | 40.14 | — | 46.42 | 61.28% | 6.06% | 2.21% | 2.70% | 2.80% | 1.17% | 0.65 | 1.01 | 2.99 | 1.66 | 4.62 | -16562.00% | 1359.00% | -10825.00% | -0.05% | 0.38 | -0.14% | 0.00% | 0.00% | 4.67% | 73.84 | -2167.72 | 4.47 | 3.19 |
| BGM | BGM Group Ltd. | $1.11 | 222.69M | +3,719% | +391% | +343% | +545% | -40.44 | 1.44 | 2.44 | 49.11 | — | 1.61 | 16.39% | -2.25% | -5.75% | -3.55% | -1.76% | -2.91% | 0.00 | -0.88 | 3.39 | 2.73 | -11.16 | -8148.00% | -4599.00% | -43.00% | -5.52% | 0.06 | -14.87% | 0.00% | 0.00% | 4.76% | -76.65 | -12.76 | 1.72 | 5.16 |
| CLOV | Clover Health Investments… | $2.09 | 1.08B | +1,430% | +6,971% | — | — | -12.33 | 3.42 | 0.55 | -11.45 | -13.17 | 3.45 | 103.58% | -4.44% | -4.45% | -26.33% | -51.38% | -15.25% | 0.00 | — | 1.47 | 0.46 | 0.93 | 9362.00% | 4034.00% | -30721.00% | -6.54% | -0.32 | -41.43% | 0.00% | 0.00% | 0.10% | -11.22 | -13.92 | 0.50 | 0.06 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GRDN | Guardian Pharmacy Service… | $33.51 | 2.12B | -11% | +240% | — | — | -16.12 | 8.03 | 0.93 | -27.12 | — | 19.59 | 19.89% | -5.12% | -7.11% | -83.14% | -46.27% | -24.00% | 0.26 | -19.19 | 1.05 | 0.71 | -0.75 | -55385.00% | 1742.00% | -2608.00% | 3.63% | 0.40 | 30.59% | 3.12% | -50.30% | 11.06% | -18.72 | 28.32 | 0.96 | 7.31 |
| INSP | Inspire Medical Systems, … | $64.51 | 1.87B | +102% | +157% | -20% | +62% | 13.09 | 2.44 | 2.09 | 25.07 | 7.29 | 2.44 | 85.39% | 5.59% | 15.95% | 19.77% | 13.05% | 16.95% | 0.04 | 371.93 | 6.08 | 4.46 | -1.12 | 17943.00% | 1360.00% | -1388.00% | 4.12% | 1.22 | 20.10% | 0.00% | 0.00% | 9.20% | 31.94 | 20.74 | 1.78 | 10.66 |
| MESO | Mesoblast Limited | $15.85 | 2.04B | +203% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| QDEL | QuidelOrtho Corporation | $22.74 | 1.54B | -6% | -60% | — | — | -1.35 | 0.80 | 0.56 | -8.47 | — | -2.38 | 46.67% | -33.67% | -41.45% | -46.15% | -18.22% | -18.56% | 1.46 | -5.18 | 1.50 | 0.64 | -5.40 | -4535.00% | -189.00% | -2596.00% | -5.42% | 0.11 | -1.65% | 0.00% | 0.00% | 0.00% | -4.50 | -49.82 | 1.51 | 0.29 |
| SSII | SS Innovations Internatio… | $4.76 | 921.64M | +1,445% | +6,162% | — | — | -85.61 | 121.83 | 79.40 | -93.41 | — | 121.83 | 40.93% | -91.90% | -92.74% | -138.00% | -81.31% | -56.44% | 1.35 | -19.50 | 1.29 | 0.36 | -1.00 | -3750.00% | 25120.00% | -3573.00% | -0.62% | -0.45 | -43.55% | 0.00% | 0.00% | 0.00% | -87.33 | -163.04 | 80.26 | 31.74 |
| TWST | Twist Bioscience Corporat… | $46.92 | 2.88B | -25% | -66% | -100% | — | -24.87 | 4.08 | 5.13 | -35.25 | — | 5.12 | 50.72% | -36.18% | -20.63% | -16.43% | -41.34% | -12.37% | 0.29 | — | 3.64 | 3.17 | 0.88 | -6389.00% | 2032.00% | 934.00% | -3.92% | -0.52 | -22.95% | 0.00% | 0.00% | 0.00% | -13.48 | -24.28 | 4.88 | 4.32 |
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
- CEO
- Larry L. Wood
- Employees
- 756
- Beta
- 0.98
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($46.70 ÷ $24.63) − 1 = +89.61% (DCF, example).